An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors

Onali, Sara;Minerba, Luigi;Fantini, Massimo C
2022-01-01

Abstract

The use of ustekinumab and vedolizumab as second-line therapies in patients with Crohn's disease (CD) in which tumour necrosis factor alpha inhibitors (TNFi) failed is still debated. The aim of this study was to compare, in a large multicenter observational retrospective cohort, the effectiveness of ustekinumab and vedolizumab as second-line therapies, as assessed by clinical and objective outcomes including endoscopy and gastrointestinal imaging.
2022
Inglese
117
8
1279
1287
9
WOS:000835887700023
2-s2.0-85135597946
35467558
Esperti anonimi
scientifica
no
Onali, Sara; Pugliese, Daniela; Caprioli, Flavio Andrea; Orlando, Ambrogio; Biancone, Livia; Nardone, Olga Maria; Imperatore, Nicola; Fiorino, Gionata ...espandi
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
30
reserved
Files in This Item:
File Size Format  
Onali et al AJG 2022.pdf

Solo gestori archivio

Type: versione post-print
Size 6.01 MB
Format Adobe PDF
& nbsp; View / Open   Request a copy
6.01 MB Adobe PDF & nbsp; View / Open   Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie